logo
New chip could be the breakthrough the quantum computing industry has been waiting for

New chip could be the breakthrough the quantum computing industry has been waiting for

Yahoo7 hours ago

When you buy through links on our articles, Future and its syndication partners may earn a commission.
Scientists have developed a new type of computer chip that removes a major obstacle to practical quantum computers, making it possible for the first time to place millions of qubits and their control systems on the same device.
The new control chip operates at cryogenic temperatures close to absolute zero (about minus 459.67 degrees Fahrenheit, or minus 273.15 degrees Celsius) and, crucially, can be placed close to qubits without disrupting their quantum state.
"This result has been more than a decade in the making, building up the know-how to design electronic systems that dissipate tiny amounts of power and operate near absolute zero," lead researcher David Reilly, professor at the University of Sydney Nano Institute and School of Physics, said in a statement.
The scientists described the result as a "vital proof of principle" for integrating quantum and classical components in the same chip — a major step toward the kind of practical, scalable processors needed to make quantum computing a reality. The researchers published their findings June 25 in the journal Nature.
Qubits are the quantum equivalent of binary bits found in today's classical computers. However, where a classical bit can represent either 0 or 1, a qubit can exist in a "superposition" of both states. This enables quantum computers to perform multiple calculations in parallel, making them capable of solving problems far beyond the reach of today's computers.
Related: Quantum computers that are actually useful 1 step closer thanks to new silicon processor that could pack millions of qubits
Spin qubits, a type of qubit that encodes information in the spin state of an electron, have piqued the interest of scientists because they can be built using complementary metal-oxide-semiconductor (CMOS) technology.
This is the same process used to fabricate the chips found inside modern smartphones and PCs. In theory, this makes spin qubits much easier to produce at scale as it slips into normal manufacturing methods.
Other quantum computers use different types of qubits, including superconducting, photonic or trapped-ion qubits. But unlike these other types, spin qubits can be made on a massive scale using existing equipment.
However, spin qubits need to be kept at temperatures below 1 kelvin (just above absolute zero) to preserve "coherence." This is a qubit's ability to maintain superposition and entanglement over time, and what is needed to unlock the parallel processing power that makes quantum computing so promising. Spin qubits also need electronic equipment to measure and control their activity.
"This will take us from the realm of quantum computers being fascinating laboratory machines to the stage where we can start discovering the real-world problems that these devices can solve for humanity," Reilly added.
Integrating the electronics required to control and measure spin qubits has long posed a challenge, as even small amounts of heat or electrical interference can disrupt the qubits' fragile quantum state.
But this new, custom CMOS chip is designed to operate in cryogenic environments and at ultra-low power levels, meaning it can be integrated onto a chip alongside qubits without introducing thermal or electrical noise that would otherwise interrupt coherence.
In tests, the researchers ran single-gate and two-qubit gate operations with the control chip positioned less than 1 millimeter (0.04 inches) from the qubits. The control chip introduced no measurable electrical noise and caused no drop in accuracy, stability or coherence, the researchers said.
Additionally, the control chip consumed just 10 microwatts (0.00001 watts) of power in total, with the analogue components — used to control the qubits with electrical pulses — using 20 nanowatts (0.00000002 watts) per megahertz.
"This validates the hope that indeed qubits can be controlled at scale by integrating complex electronics at cryogenic temperatures," Reilly said.
"This will take us from the realm of quantum computers being fascinating laboratory machines to the stage where we can start discovering the real-world problems that these devices can solve for humanity," he added.
"We see many further diverse uses for this technology, spanning near-term sensing systems to the data centres of the future."
RELATED STORIES
—Quantum computing: What is quantum error correction (QEC) and why is it so important?
—IBM will build monster 10,000-qubit quantum computer by 2029 after 'solving science' behind fault tolerance — the biggest bottleneck to scaling up
—World's first silicon-based quantum computer is small enough to plug into a regular power socket
The findings could prompt more researchers to explore the power of spin qubits.
"Now that we have shown that milli-kelvin control does not degrade the performance of single- and two-qubit quantum gates, we expect many will follow our lead," study co-author Kushal Das, senior hardware engineer at Emergence Quantum and a researcher at the University of Sydney who designed the chip, said in the statement.
"Fortunately for us, this is not so easy but requires years to build up the know-how and expertise to design low-noise cryogenic electronics that need only tiny amounts of power."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Quantum Computing (QUBT) Loses 7.3% on Sudden Management Shakeup
Quantum Computing (QUBT) Loses 7.3% on Sudden Management Shakeup

Yahoo

timean hour ago

  • Yahoo

Quantum Computing (QUBT) Loses 7.3% on Sudden Management Shakeup

Quantum Computing Inc. (NASDAQ:QUBT) is one of the . Quantum Computing fell for a third straight day on Monday, losing another 7.31 percent to close at $17.50 apiece as investor sentiment was dampened by a sudden management shakeup in the company. This followed the sudden retirement of Christopher Boehmler as Quantum Computing Inc.'s (NASDAQ:QUBT) chief finance officer, effective last Thursday, June 19. While Quantum Computing Inc. (NASDAQ:QUBT) said that Boehmler's decision was not due to any management disagreement, his sudden resignation was received in a negative light. Boehmler was replaced by Christopher Roberts, 70, who was the company's CFO between 2018 and 2023, before serving as a consultant from 2023 to 2025. In other news, Quantum Computing Inc. (NASDAQ:QUBT) said it was able to raise $200 million in fresh funds through the private placement of more than 14 million common shares at a price of $14.25 apiece. A data analyst pouring over a chart, the intricacies of its lines being revealed. Quantum Computing Inc. (NASDAQ:QUBT) said it plans to use the proceeds to accelerate commercialization efforts, strategic acquisitions, working capital, and general corporate purposes. While we acknowledge the potential of QUBT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Scanfil Strengthens its Customer Portfolio in Medtech & Life Science by Signing Agreement with Liquid Instruments
Scanfil Strengthens its Customer Portfolio in Medtech & Life Science by Signing Agreement with Liquid Instruments

Yahoo

timean hour ago

  • Yahoo

Scanfil Strengthens its Customer Portfolio in Medtech & Life Science by Signing Agreement with Liquid Instruments

MELBOURNE, Australia, June 26, 2025--(BUSINESS WIRE)--Scanfil and Liquid Instruments have signed a manufacturing outsourcing agreement for Scanfil's Melbourne plant in Australia. This agreement supports Liquid Instruments' strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub. "We're continuing to expand our manufacturing footprint in Australia," says Daniel Shaddock, CEO of Liquid Instruments. "Onshoring production through this partnership allows us to scale more efficiently, while deepening our investment in Australia's technology ecosystem. Scanfil's expertise and strong local presence make them the ideal partner for this next phase of growth." The collaboration will leverage Scanfil's and its subsidiary, SRXGlobal's, expertise in Medtech & Life Science. Liquid Instruments will benefit from supply chain management, scalable manufacturing, global delivery capabilities, and aftermarket services — all in Victoria, Australia. "Liquid Instruments has developed a unique product with an interesting and complex technology that is a perfect fit for the services provided by SRXGlobal in Australia. We at Scanfil and SRXGlobal are thrilled and excited that Liquid Instruments has chosen SRXGlobal as their preferred manufacturing partner for the exciting journey ahead, and we look forward to a strong and successful partnership", states Christian Kesten, VP of Scanfil APAC. Scanfil in brief Scanfil plc is Europe's largest listed provider of electronics manufacturing services (EMS), whose turnover in 2024 amounted to EUR 780 million. The company serves global sector leaders in the customer segments of Industrial, Energy & Cleantech, and Medtech & Life Science. The company's services include design services, prototype manufacture, design for manufacturability (DFM) services, test development, supply chain and logistics services, circuit board assembly, manufacture of subsystems and components, and complex systems integration services. Scanfil's objective is to grow customer value by improving their competitiveness and by being their primary supply chain partner and long-term manufacturing partner internationally. Scanfil's longest-standing customer account has continued for more than 40 years. The company has global supply capabilities and eleven production facilities across four continents. View source version on Contacts Further information:Christian KestenVice President, APAC regiontel. +86 512 67168867 Pasi HiedanpääDirector, Investor Relations and Communicationstel. +358 50 378 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Womb lining test offers miscarriage hope to women
Womb lining test offers miscarriage hope to women

Yahoo

time2 hours ago

  • Yahoo

Womb lining test offers miscarriage hope to women

UK scientists say they have developed a test which can help identify women with an abnormal womb lining that increases their risk of miscarriage. They say their work could pave the way for new treatments for those going through repeated pregnancy loss. In some women with a history of miscarriage, the womb lining doesn't react the way it should - transforming into a supportive place for the embryo to implant, the Warwick University team discovered. Charities say the findings could help provide an explanation, in some cases, for the trauma and devastation of recurrent miscarriage. Around one in six of all pregnancies are lost, most before twelve weeks, and each miscarriage increases the risk of another one happening. To date, most research in this area has focused on the quality of the embryo, with much less known about the role of the womb lining. Dr Jo Muter, study author and researcher at Warwick Medical School, said: "Many women are told they've just had 'bad luck', but our findings show that the womb itself may be setting the stage for pregnancy loss, even before conception takes place." The job of the womb lining is to receive the embryo and help it develop during pregnancy, thanks to a reaction which converts cells into a different, supportive state. But when that reaction is messed up and doesn't fully happen, the risk of bleeding and early pregnancy rises. Once a woman has had one faulty reaction, she is more likely to have another, the researchers say. They've developed a new test which can measure signs of a healthy or defective reaction in the womb lining, which is being piloted to help more than 1,000 patients at Tommy's National Centre for Miscarriage Research at University Hospital Coventry & Warwickshire (UHCW). Charlie Beattie, 37, had countless early miscarriages over the course of four years, to the point where "a positive pregnancy test wasn't exciting any more", she says. She and her husband Sam, from Leamington Spa, felt devastated and resigned to considering other options for having a family. Then they found out about at a trial taking place at the miscarriage research centre. Charlie had a sample of her womb taken, and the new test showed it was not "hospitable for babies", she says. After taking the drug sitagliptin for three months, she had a pregnancy which finally stuck - and nine-week-old June is the joyful result. "She's a tiny miracle. It doesn't feel real," says Charlie. She admits being anxious all the way through her pregnancy until June was safely in her arms. Even the pregnancy scans were a new experience. "We'd never seen anything on a scan before that moved," she says. "When they said 'I can see it, it's in the right place', we both burst into tears." Anyone can refer themselves to the clinic, but it has a long waiting list and funding issues mean patients must contribute to the cost of the test. Dr Jyotsna Vohra, director of research at Tommy's, said care and treatment for those who experience pregnancy or baby loss varied unacceptably across the UK. "There should be no barriers to accessing any test or treatment that has been proven to make a difference. "We hope NHS decision-makers will look carefully at the results of the Coventry pilot project and consider rolling this test out nationwide, so that everyone who might benefit has that opportunity." Dr Muter says the next step is to use the test to assess potential drug treatments. Sitagliptin, usually used to treat diabetes, is the go-to option for womb lining issues but there may be other existing drugs which can be repurposed, she added. With 80% of drugs not tested on pregnant women, it's unclear which ones might be effective.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store